Jul 28, 2026 06:00AM
Jul 28, 2026 06:00AM
Jul 27, 2026 04:00PM
Jul 27, 2026 04:00PM
Jul 14, 2026 05:50AM
Jul 14, 2026 02:30AM
May 12, 2026 06:30AM ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Apr 13, 2026 07:30AM
Mar 25, 2026 08:00AM
Mar 18, 2026 08:00AM
Mar 18, 2026 08:00AM
Feb 4, 2026 04:05PM
Dec 18, 2025 07:30AM
Dec 18, 2025 07:30AM ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Dec 10, 2025 07:30AM
Dec 10, 2025 07:30AM
Dec 1, 2025 07:30AM
Dec 1, 2025 07:30AM
Dec 1, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 12, 2025 07:00AM ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Nov 3, 2025 04:05PM
Oct 22, 2025 07:31AM
Oct 22, 2025 07:30AM
Sep 3, 2025 07:00AM
Sep 3, 2025 07:00AM
Aug 13, 2025 07:00AM
Aug 13, 2025 07:00AM ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Jul 29, 2025 08:00AM
Jul 29, 2025 08:00AM
Jul 22, 2025 06:40AM
Jul 21, 2025 08:04AM
Jul 21, 2025 08:00AM
Nov 14, 2023 04:30PM
Aug 14, 2023 05:33PM ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Jul 17, 2023 07:00AM
May 15, 2023 05:00PM
May 8, 2023 09:00AM
May 8, 2023 09:00AM
Apr 10, 2023 07:30AM
Apr 10, 2023 07:30AM
Apr 10, 2023 07:30AM ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
Mar 29, 2023 08:31AM
Mar 29, 2023 08:30AM
Mar 29, 2023 08:30AM
Mar 8, 2023 05:06PM
Mar 8, 2023 05:06PM
Nov 14, 2022 07:00AM
Nov 14, 2022 07:00AM ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights
Oct 12, 2022 07:00AM

326,675 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All